Advanced glycation end products (AGEs) are a heterogeneous group of bioactive molecules endogenously generated by a nonenzymatic reaction between reducing sugars and amine residues on proteins, lipids, or nucleic acids. 1, 2 AGEs can also be exogenously inhaled from cigarette smoking 3 or ingested from diets. 4 The major site of AGE clearance is the kidney. 5 AGEs, therefore, may accumulate in the body as a consequence of overgeneration or overintake and in the presence of renal function impairment. AGEs often accumulate intracellularly and activate intracellular signaling pathways and modify the function of intracellular proteins. 6 AGEs may also circulate and act on cell surface receptors, such as the receptors for AGEs, and trigger the activation of secondary messenger pathways, such as protein kinase. 2, 7 The clinical relevance of AGEs for the cardiovascular system is the modification of extracellular matrix proteins in the cardiac and vessel wall. 7 The glycation process may lead to the formation of intermolecular and intramolecular crosslinks with collagen and, in turn, to increased arterial stiffness and structural changes. 8 Indeed, AGEs crosslinking on type 1 collagen and elastin may lead to increased arterial stiffness. 9 Inhibition of AGE formation by aminoguanidine may improve arterial compliance in humans. 10 Because of the complexity in the distribution and composition of AGEs, the measurement of AGEs is complex. Nonetheless, in several clinical studies, the level of circulating AGEs has been linked to arterial stiffness [11] [12] [13] and cardiovascular-renal disease. [14] [15] [16] [17] [18] In this population-based study, we investigated the association of plasma AGE concentration with arterial stiffness and wave reflections as assessed by carotid-femoral pulse wave velocity (cfPWV) and central (cAI) and peripheral augmentation indices (pAI), respectively.
Methods study population
This cross-sectional analysis was based on the data of an ongoing population study on multiple cardiovascular risk factors in Shanghai, China. 19 The study subjects were recruited from a newly established residential area in the suburb of Shanghai, 30 kilometers from the city center. Most residents were immigrants from the nearby villages since 2003 and had previously farmed or done other agricultural work. The Ethics Committee of Ruijin Hospital, Shanghai Jiaotong University School of Medicine approved the study protocol. All subjects gave written informed consent.
In the year 2009, we invited 1,630 residents to take part in our study. Of those invited, 1,192 (73.1%) participated. We excluded 141 subjects from our analysis because they did not have blood samples collected (n = 22) or did not have arterial (n = 93) or anthropometric measurements (n = 26). Thus, the total number of subjects included in the present analysis was 1,051.
Field work
One experienced physician measured each participant's blood pressure 5 times consecutively by standard mercury sphygmomanometry after the subjects had rested for at least 5 minutes in the sitting position. These 5 blood pressure readings were averaged for analysis. Mean arterial pressure was calculated as one-third systolic plus two-thirds diastolic blood pressures. The same observer also administered a standardized questionnaire to collect information on medical history, smoking habit, alcohol intake, and the use of medications. Hypertension was defined as a sitting blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic or as the use of antihypertensive drugs. A trained technician performed anthropometric measurements.
arterial stiffness and wave reflections
A trained technician performed measurements of pulse wave velocity and pulse wave analysis after subjects had rested for 15 minutes in the supine position by the use of applanation tonometry. Subjects were asked to refrain from smoking, rigorous exercise, and drinking alcohol or caffeinecontaining beverages for at least 2 hours before the examination. We used a high-fidelity SPC-301 micromanometer (Millar Instruments, Houston, TX) interfaced with a laptop computer running the SphygmoCor software, version 7.1 (AtCor Medical, West Tyde, New South Wales, Australia) to record arterial waveforms.
For the measurement of cfPWV, the operator recorded in succession the right carotid and femoral waveforms (12 seconds each). With the simultaneously recorded electrocardiogram (lead 2), the time delay between the foot of the 2 pressure waveforms was taken as the transit time between carotid and femoral pressure waves. The distance traveled by the pressure wave was the difference between the distances from sternal notch to the femoral location and from sternal notch to the carotid location. PWV was calculated as the distance traveled divided by the transit time.
For the measurement of cAI and pAI, the operator recorded the radial arterial waveform at the dominant arm (8 seconds). Recordings were discarded when the variability of consecutive waveforms exceeded 5% or when the amplitude of the pulse wave signal was <80 mV. We calibrated the pulse wave by brachial systolic and diastolic blood pressures (the average of 2 consecutive readings) in the supine position immediately before the SphygmoCor recordings using a validated Omron 705CP oscillometric blood pressure monitor (Omron, Kyoto, Japan). From the radial signal, the SphygmoCor software calculates the aortic pulse wave by means of a validated generalized transfer function. The pAI (radial) was the ratio of the second to the first peak of the pressure wave expressed in percentage. The cAI (aortic) was the difference between the second and first systolic peaks given as a percentage of the aortic pulse pressure.
By repeat examination of 16 subjects at a mean time interval of 1 hour, we computed the coefficient of variation as SD of the within-subject differences divided by the mean of all measurements. The intra-observer coefficients of variability were 9.2%, 6.7%, and 2.5% for the cAI, pAI, and cfPWV, respectively.
laboratory methods
Venous blood samples were drawn after overnight fasting for biochemical measurements. Plasma AGE concentration was measured by the enzyme-linked immunosorbent assay method (AGEs ELISA Kit, Cusabio Biotech, Wilmington, DE). The within-assay and between-assay coefficients of variation were 9.9% and 10.9%, respectively. Plasma glucose concentration and serum total and high-density lipoprotein (HDL) cholesterol and serum triglycerides were measured by a clinical chemistry automatic analyzer (Hitachi 7600-020, Tokyo, Japan).
Diabetes mellitus was defined as a plasma glucose concentration of at least 126 mg/dl fasting or 200 mg/dl at any time or as the use of antidiabetic agents. Prediabetes was defined as a plasma fasting glucose in the range of 110-125 mg/dl.
statistical analysis
For database management and statistical analysis, we used SAS software (version 9.13; SAS Institute, Cary, NC). Departure from normality was tested by the Shapiro-Wilk's statistic. Plasma AGE concentration was not normally distributed and was, therefore, logarithmically transformed for statistical analysis. Means and proportions were compared with the Student t test and Fisher exact test, respectively. We searched for possible correlates using stepwise multiple regression with the P value for covariables to enter and stay in the model set at 0.10. We then performed multiple regression analyses to study the associations of plasma AGE concentration with cfPWV, cAI, and pAI, while controlling for the identified correlates. The 1,051 participants included 663 (63.1%) women, 90 (8.6%) diabetic and prediabetic patients, and 390 (37.1%) hypertensive patients, of whom 308 (29.3%) took antihypertensive drugs. Table 1 shows the characteristics of the study participants by sex. Men and women had similar characteristics, except (P ≤ 0.03) that men were older (+1.8 years) and had a greater body mass index (+0.6 kg/m 2 ), higher diastolic blood pressure (+3.2 mm Hg), higher serum triglycerides (+27.5 mg/dl), lower serum HDL cholesterol concentration (−7.7 mg/dl), and higher proportions of current smoking (49.0% vs. 0.3%) and alcohol intake (35.1% vs. 1.4%).
Men, compared with women, had higher plasma AGE concentration (5.62 vs. 5.07 μg/ml; P = 0.02) and cfPWV (7.9 vs. 7.6 m/s; P = 0.004) but lower cAI (24.8% vs. 30.6%; P < 0.0001) and pAI (78.3% vs. 86.4%; P < 0.0001). In addition, plasma AGE concentration was significantly (P ≤ 0.04) higher with older age and greater serum total/HDL cholesterol ratio in men as well as in women (Figure 1 ).
correlates of plasma age concentration and arterial stiffness and wave reflections
In sex-specific stepwise multiple regression analyses, we considered as potential correlates age, body height and body weight (body mass index for cfPWV), mean arterial pressure, pulse rate, current smoking and alcohol intake (not in women because of small numbers), the use of antihypertensive drugs, the presence of diabetes mellitus or prediabetes, and serum total/HDL cholesterol ratio.
We identified that plasma AGE concentration was associated with age and serum total/HDL cholesterol ratio and cfPWV, cAI, and pAI were associated with age, mean arterial pressure, pulse rate, and anthropometry in men as well as in women (r = 0.07-0.56 or −0.48 to −0.07; P ≤ 0.06) ( Table 2) . cfPWV was additionally associated with current smoking in men (r = −0.07; P = 0.09) and with the use of antihypertensive drugs in women (r = 0.08; P = 0.003). Both cAI and pAI were additionally associated with current smoking (r = 0.08-0.09; P ≤ 0.01) and the presence of diabetes or prediabetes in men (r = 0.08-0.10; P ≤ 0.02). cAI was additionally associated with serum total/HDL cholesterol ratio in women (r = 0.08; P = 0.003) ( Table 2) .
relationship between plasma age concentration and measurements of arterial stiffness and wave reflections Because men and women had similar correlates of plasma AGEs and measurements of arterial stiffness and wave reflections, we combined men and women in further multiple regression analyses and adjusted for above-identified correlates (i.e., sex, age, mean arterial pressure, pulse rate, body height and body weight (body mass index for cfPWV), current smoking, the presence of diabetes or prediabetes, the use of antihypertensive drugs, and serum total/HDL cholesterol ratio). These multiple regression analyses demonstrated that plasma AGE concentration was significantly associated with cAI (1.9% increase per 10-time increase in plasma AGE concentration; P = 0.02) and pAI (4.0% increase per 10-time Values are arithmetic mean ± SD or geometric mean (95% confidence interval) or number of subjects (%). For definitions of hypertension, diabetes mellitus, and prediabetes, see Methods.
Abbreviations: AGE, advanced glycation end product; HDL, high-density lipoprotein.
increase in plasma AGE concentration; P = 0.003) but not with cfPWV (P = 0.62) (Table 3 ). However, there was significant (P = 0.001) interaction between plasma AGE concentration and age in relation to cfPWV. Only in subjects aged ≥70 years, cfPWV increased with higher levels of plasma AGE concentration (bottom vs. top quintile = 8.10 ± 1.64 vs. 8.90 ± 1.67 m/s; P = 0.02) (Figure 2 ). Further subgroup analyses demonstrated that the associations between plasma AGE concentration and cAI or pAI did not statistically differ across sex, age, body mass index, current smoking, hypertension, use of antihypertensive medication, diabetes or prediabetes, and serum total cholesterol (P ≥ 0.09) (Table 3) . Nonetheless, the association tended to be stronger in younger subjects than in older subjects (P = 0.09). Plasma AGE concentration was significantly associated with cAI and pAI in subjects aged <60 years (P ≤ 0.01) but not in those aged 61-69 years or those aged ≥70 years (P ≥ 0.19). In addition, the associations between plasma AGEs and cfPWV tended to be stronger in subjects aged ≥70 years or with normal weight, hypertension, or serum total cholesterol ≥200 mg/dl (P ≤ 0.06) ( Table 3) .
discussion
The main finding of our study is that AGEs accumulate with advancing age and higher serum total/HDL cholesterol ratio and are associated with arterial wave reflections as assessed by cAI and pAI and, in an age-dependent manner, with arterial stiffness as assessed by cfPWV. Furthermore, the latter association tends to be stronger in subjects with normal weight, hypertension, or higher serum total cholesterol.
Our study is the first that has demonstrated significant association between plasma AGE concentration and arterial wave reflections as assessed by cAI and pAI. The discrepancy between our finding and the results of a previous study 11 might be explained by the difference in the sample size between the 2 studies. In 30 untreated hypertensive patients and 16 normotensive controls, McNulty et al. 11 measured plasma AGEs with an anti-AGE monoclonal antibody that recognizes N ε -carboxymethyl lysine (CML) and cross-reacts with N ε -carboxyethyl lysine (CEL) and reported similar levels of plasma AGEs (7.1 μg/ml in men vs. 5.1 μg/ ml in women) as our study. However, in this previous study, plasma AGE concentration was not associated with cAI. This previous study apparently has insufficient power to show association of the size observed in our study.
In spite of convincing experimental evidence on the role of AGE accumulation in the pathogenesis of arteriosclerosis, the results of studies on the association of various measures of AGEs, such as plasma AGEs 11, 16 or CML concentration 12, 20 or skin autofluorescence, 21, 22 with arterial stiffness as assessed by carotid-femoral 11, 12, 20, 21 or brachial-ankle PWV 16, 22 have been conflicting. Even in studies that had similar measurements of AGEs and PWV, the results are inconsistent or even contradictory. In the abovementioned study in 46 subjects, 11 the logarithmically transformed plasma AGE concentration was closely associated with cfPWV (r = 0.49; P < 0.001). Two studies that similarly measured CML and cfPWV reported divergent levels of CML (0.47 ± 0.13 μg/mL 12 vs. 0.21 ± 0.04 μg/mL 20 ) and similar levels of cfPWV (6.6 ± 1.8 m/s 12 vs. 6.8 ± 2.2 m/s 20 ) and produced inconsistent results. In a relatively healthy community-dwelling adult population, each SD increase in plasma CML concentration was associated with 0.16 m/s (P = 0.02) and 0.18 m/s (P = 0.009) increase in cfPWV in all (n = 493) and nondiabetic subjects (n = 469), respectively. 12 However, in a similar population-based study with a smaller sample size (n = 102), plasma CML concentration was not associated with cfPWV (P = 0.23), although subjects with a plasma CML concentration above the median (0.20 μg/mL) did have a significantly greater carotid diameter than those below the median (486 μm vs. 421 μm; P < 0.05). 20 Our findings add both clarity and complexity to the issue of the relationship between AGEs and arterial stiffness. We measured plasma AGE concentration and cfPWV in a much larger population-based sample, which provided the possibility to find weak and context-dependent associations. Both AGEs and arterial stiffness are highly dependent on age and several other cardiovascular risk factors, such as hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking, and so on. Aging often aggregates these cardiovascular risk factors. The observed significant interaction between AGEs and age in relation to cfPWV in this study may indicate that AGE accumulation requires time to reach the level of effect on the vessel wall. As evidenced by previous mechanistic 23 and interventional studies, 10,24 AGE accumulation might be indeed a possible mechanism for the development and progression of arteriosclerosis and a potential therapeutic target for the prevention of cardiovascular disease. In a sex-specific stepwise multiple regression model, we considered age, body height and body weight (body mass index for carotid femoral pulse wave velocity), mean arterial pressure, pulse rate, current smoking and alcohol intake (not in women because of small numbers), the use of antihypertensive drugs, the presence of diabetes or prediabetes, and serum total/high-denisity lipoprotein (HDL) cholesterol ratio for entry and stay at a significance level of P ≤ 0.10. The variables are listed in an order of the size of the absolute value of the correlation coefficients in men. For definitions of hypertension, diabetes mellitus and prediabetes, see Methods.
The discrepancy of our observations on cfPWV and cAI or pAI is not completely understood. cfPWV measures large arterial stiffness, whereas cAI or pAI measures arterial wave reflections that are mainly dependent on structural and functional changes in the peripheral circulation. There is at least 1 experimental study in elderly dogs with experimental hypertension that suggested that AGEs accumulate in vascular smooth muscle cells and change the vasculature. 25 In this case, small vessels without adventitia should be more susceptible for injury by the AGE mechanism than large arteries, and the effect of AGEs on small arteries appears earlier than on large arteries. In addition, as indicated by 2 clinical trials of alagebrium, an inhibitor of AGE formation, in patients with systolic (>140 mm Hg) hypertension and widened pulse pressure (>60 mm Hg) 10 and diastolic heart failure, 26 respectively, and as suggested by O'Rourke, 27 the therapeutic mechanism of drugs targeting AGEs might be through effects on peripheral arteries rather than the aorta.
Our finding on the association between plasma AGE concentration and total/HDL cholesterol ratio is consistent with the results of previous studies. 11, 28 The association is probably because hyperlipidemia may increase the production of AGEs and decease the clearance of circulating plasma AGEs by binding to lipoproteins. However, we did not find association between AGEs and impaired glucose metabolism. The low prevalence of diabetes mellitus or prediabetes in our study population might be an explanation.
A major limitation of our study is its cross-sectional design, which does not allow us to draw any casual inference. In addition, we measured plasma AGE concentration but did not differentiate various components of AGEs, such as CML, N ε -carboxyethyl lysine, pentosidine, and so on. These components may have different effects on the arterial system. Our study included more women than men. Nonetheless, men and women had quite similar correlates of plasma AGE concentration and measurements of arterial stiffness and wave reflections.
In conclusion, AGEs accumulate with aging and high cholesterol and are associated with increased arterial wave reflections and, in an age-dependent manner, with arterial stiffness, especially on the conditions of normal body weight, hypertension, and hypercholesterolemia. One of the clinical implications of our study is that prospective observational and interventional studies are warranted to study the risk and reversibility of AGE accumulation in cardiovascular prevention. In spite of the failure in bringing alagebrium to a successful pharmaceutical, the scientific community and the industry should not give up the The analysis was adjusted for sex, age, body height and body weight (body mass index for cfPWV), mean arterial pressure, pulse rate, the use of antihypertensive drugs, the presence of diabetes mellitus or prediabetes, current smoking, and serum total/high-density lipoprotein cholesterol ratio, as appropriate. Values are regression coefficient (β) ± SE, computed for each 10-time increase in plasma AGE concentration. P int indicates P value for interaction between plasma AGEs and the subgroup factors under study. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
pathway of AGEs in the development of novel drugs for vascular protection and prevention. Relationship between carotid femoral pulse wave velocity (cfPWV) and plasma advanced glycation end product (AGE) concentration by age subgroup. The regression line was drawn according to the mean values of cfPWV per quintile of plasma AGE concentration. The analysis was adjusted for sex, body mass index, mean arterial pressure, pulse rate, the presence of diabetes mellitus or prediabetes, current smoking, the use of antihypertensive drugs, and serum total/high-density lipoprotein cholesterol ratio. P int indicates P value for the interaction between age and plasma AGE concentration in relation to cfPWV, analyzed as continuous variables.
